SCHEMBL30329752

SCHEMBL30329752

CNc1cc(C)nc(Nc2cc(O)c3c(c2)OCCO3)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABCB1 P08183 1/20 0.40
▸ ABCC1 P33527 1/20 0.40
▸ ABCG2 Q9UNQ0 1/20 0.40
▸ KMT2A Q03164 5/20 0.34
▸ MEN1 O00255 4/20 0.34
▸ NPSR1 Q6W5P4 2/20 0.34
▸ HPGD P15428 1/20 0.34
▸ SMN1; SMN2 Q16637 4/20 0.34
▸ MAPK1 P28482 3/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ TSHR P16473 2/20 0.33
▸ HSD17B10 Q99714 2/20 0.33
▸ ALDH1A1 P00352 2/20 0.33
▸ RHOA P61586 1/20 0.33
▸ NOS3 P29474 1/20 0.33
▸ NOS2 P35228 1/20 0.33
▸ NPC1 O15118 3/20 0.33
▸ RAB9A P51151 3/20 0.33
▸ RXFP1 Q9HBX9 1/20 0.33
▸ HTT P42858 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30329704 0.90 NPC1 (0.38) ABCB1ABCC1ABCG2KMT2AMEN1
SCHEMBL25166455 0.90 NPC1 (0.38) ABCB1ABCC1ABCG2KMT2AMEN1
SCHEMBL30329759 0.82 ABCB1 (0.38) ABCB1ABCC1ABCG2MAPK1L3MBTL1
SCHEMBL25166156 0.82 ABCB1 (0.38) ABCB1ABCC1ABCG2MAPK1L3MBTL1
SCHEMBL30330211 0.75 ABCB1 (0.36) ABCB1ABCC1ABCG2KMT2AMEN1
SCHEMBL30329678 0.75 ABCB1 (0.36) ABCB1ABCC1ABCG2KMT2AMEN1
SCHEMBL25166190 0.74 EHMT2 (0.51) ABCB1ABCC1ABCG2SMN1; SMN2
SCHEMBL30329919 0.74 EHMT2 (0.51) ABCB1ABCC1ABCG2SMN1; SMN2
SCHEMBL25166243 0.73 EHMT2 (0.49) ABCB1ABCC1ABCG2MAPTLMNA
SCHEMBL30329782 0.73 EHMT2 (0.49) ABCB1ABCC1ABCG2MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240368139-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. 2024-11-07 — — US disclosed
CN-118647610-A Novel modulators of EHMT1 and EHMT2 and therapeutic uses thereof 探戈医药股份有限公司 2024-09-13 — — CN disclosed
EP-4416143-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF Tango Therapeutics, Inc. (US) 2024-08-21 — — EP disclosed
WO-2023064586-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. (US) 2023-04-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368139-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF EHMT1, EHMT2, SHMT1 ABCB1 496/4885ABCC1 324/4885ABCG2 1630/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback